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Background: Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological entity characterized
clinically by headache, altered mental status, seizures, visual disturbances, and other focal neurological signs, and
radiographically by reversible changes on imaging. A variety of different etiologies have been reported, but the
underlying mechanism is thought to be failed cerebral autoregulation. To the best of our knowledge, we report the
third known case of PRES in an adult receiving intermittent peritoneal dialysis (PD).
Case presentation: A 23-year-old male receiving PD was brought to hospital after experiencing a generalized seizure.
On presentation he was confused and hypertensive. An MRI brain was obtained and showed multiple regions of cortical
and subcortical increased T2 signal, predominantly involving the posterior and paramedian parietal and occipital lobes
with relative symmetry, reported as being consistent with PRES. A repeat MRI brain obtained three months later showed
resolution of the previous findings.
Conclusion: Due to having a large number of endothelium-disrupting risk factors, including hypertension, uremia, and
medications known to disrupt the cerebrovascular endothelium, we suggest that those with end-stage renal disease
(ESRD) receiving PD are at high risk of developing PRES. Furthermore, we surmise that PRES is likely more prevalent in
the ESRD population but is under recognized. Physicians treating those with ESRD must have a high index of suspicion
of PRES in patients presenting with neurological disturbances to assure timely diagnosis and treatment.
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Posterior reversible encephalopathy syndrome (PRES) is
a clinical and radiological condition that involves a variety
neurological manifestations and reversible white matter
changes on T2-weighed MRI sequences. PRES has its
origins in another acronym, RPLS (reversible posterior
leukoencephalopathy syndrome), coined by Hinchey and
colleagues in 1996 [1]. The term then evolved to em-
phasize the involvement of both grey and white matter,
and to make the acronym more memorable (as it has
been long thought that PRES is caused by high blood
PRESsure) [2].* Correspondence: brett.graham@usask.ca
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distribution, and reproduction in any mediumCase reports regarding PRES in patients receiving PD
are scarce. We propose that patients with end-stage renal
disease (ESRD) receiving PD are at a higher risk of devel-
oping PRES due to both cerebral dysregulation and endo-
thelial dysfunction, secondary to complications of ESRD
and side-effects of medications they receive. Furthermore,
we surmise that PRES is likely more prevalent than previ-
ously thought in the ESRD population, and only extreme
cases heralded by seizure are brought to medical attention,
or alternatively, recognized by healthcare practitioners.
Case presentation
A 23-year old male with ESRD secondary to IgA ne-
phropathy was brought to home hospital for generalized
seizure activity. He was known to have poor compliance
with his intermittent peritoneal dialysis (PD), administer
four times per day, and had apparently missed his last two
treatments. He did not have a recent peritoneal equilibriumed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pressure exceeding 182/107 mmHg and was described as
being combative and confused. Labetalol 20 mg IV, loraze-
pam 1 mg IV, and haloperidol 1 mg IV were administered
by a nurse practitioner before being transferred to the near-
est tertiary care centre. Collateral history obtained sug-
gested that the patient was complaining of headache and
blurred vision hours prior to seizing.
Other past medical history was significant for hyperten-
sion secondary to renovascular disease, as well as being a
carrier of methicillin-resistant staphylococcus aureus. His
medications included atenolol, amlodipine, ramipril, hy-
droxyzine, scheduled clonidine, erythropoetin, calcium, and
Replivite tablets. There was no family history of epilepsy.
Social history was significant for tobacco smoking and pre-
vious recreational cocaine use.
Examination at the tertiary centre revealed a temperature
of 36.8°C and a still elevated blood pressure of 200/100
mmHg. Heart rate was recorded at 63 beats per minute
and oxygen saturation was 98% on room air. General
examination revealed a rousable individual who appeared
somewhat confused, but was alert to person and place. The
remaining neurological exam, including language assess-
ment and fundoscopy, was normal. There was no menin-
gismus. Cardiovascular exam was significant for a loud S2
heart sound, but no cardiac rubs or murmurs were ap-
preciated. Respiratory and abdominal exams were non-
contributory.
Admission blood work revealed a urea of 41 mmol/L,
a serum creatinine of 1531 μmol/L, a WBC of 11.4, and
hemoglobin of 99. Serum sodium was slightly low at 129
mol/L, and potassium was elevated at 6.3 mmol/L. Cal-
cium was low at 1.93 mmol/L, phosphate was elevated
at 3.57 mmol/L, and magnesium was 1.24 mmol/L. Liver
enzymes were generally unremarkable. An EKG revealed
tall peaked T-waves consistent with hyperkalemia. A CT-
head showed multiple cortical and subcortical hypodensi-
ties involving the posterior parasagittal portions of both
parietal lobes and the medial right occipital lobe, which
was reported as being suggestive of PRES. A lumbar punc-
ture for CSF analysis to rule out meningoencephalitis was
not performed as the patient was afebrile with no signs of
meningeal irritation.
The patient was admitted to hospital for further work-
up and management. The hyperkalemia was medically
treated. Phenytoin was initiated to prevent further sei-
zures. An MRI brain was obtained and showed multiple
regions of cortical and subcortical increased T2 signal, pre-
dominantly involving the posterior and paramedian parietal
and occipital lobes with relative symmetry (Figure 1A).
There was no diffusion restriction. On the third day after
admission the patient began to have episodes of headache
and blurred vision associated with increased blood pressure,
despite achieving good volume control through in-hospitalPD and increasing his antihypertensive regimen. These epi-
sodes continued, and thus on the fifth day after admission
he was transferred to the intensive care unit to receive con-
tinuous blood pressure monitoring and control through
an intravenous labetalol infusion. Blood pressure was de-
creased to 160/80 mmHg and he was transitioned back to
oral antihypertensive medication. He was subsequently
discharged from hospital and follow-up MRI brain three
months later showed complete resolution of previously
noted findings (Figure 1B).
Discussion
Clinically, PRES is characterized by visual disturbances,
headache, nausea, change in mental status, and seizure. Sei-
zures are cited as the commonest manifestation of PRES,
occurring in up to 90% of reported cases [3,4]. Seizure type
is mainly generalized, but focal onset has been reported [5].
Visual disturbances can range from complaints of blurred
vision to cortical blindness [5]. Symptoms develop over
hours and can persist for weeks, depending on the severity
and the latency in initiating proper treatment.
Acute hypertension is also associated with the majority
of PRES cases, but is not necessary for the diagnosis, and
the degree of elevation varies [6]. Cases with normal or
low-normal blood pressure values have been reported [7-9],
but it has been suggested that the rapid increase in blood
pressure rather than the absolute value delivers the most
risk [6,10]. Bartynski and Boardman [11] found no correl-
ation between absolute blood pressure and clinical and
radiographic presentations of PRES.
Radiographically, PRES is heralded by relatively symmet-
ric, reversible T2 hyperintensities affecting the posterior
aspects of the brain, namely the occipital and parietal
lobes [1]. It is now known that this description is more of
a general rule, and that asymmetric pictures can be seen,
and can involve the deep grey matter as well as the frontal
and temporal lobes [12]. The advent of diffusion weighted
imaging helped clarify that the MRI changes were not due
to ischemia or cytotoxic edema, but due to vasogenic
edema [13]. However, there are cases that involve some
degree of diffusion restriction, suggesting that ischemia
can be a complication of PRES [13].
Bartynski and Boardman [11] described four primary
variations of the typical PRES imaging pattern after review-
ing the imaging of 136 patients with PRES. Practically all
patients (134/136) had the classic posterior occipital or
parietal pattern, but differences were seen in the in-
volvement of the frontal lobes and other structures. A
holohemispheric watershed pattern was seen in 31 pa-
tients, where vasogenic edema followed the watershed
territories between the main cerebral arteries. A superior
frontal sulcus pattern was seen in 37 patients, where vaso-
genic edema stretched forward along the superior frontal
sulcus, sparring the extreme frontal poles. A dominant
Figure 1 Axial MRI brain of patient. In panel A, there are T2-FLAIR hyperintensities involving the paramedian parietal and occipital lobes,
suggesting vasogenic edema. T2-weighted images in panel B were taken three months after discharge and show a resolution of the abnormalities,
confirming the diagnosis of PRES.
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where there was no involvement of the frontal lobes and
variable involvement of the temporal lobes. Partial expres-
sions of the primary patterns were also noted in 38 of the
patients and atypical lesions involving the basal ganglia,
brainstem, and deep white matter were seen in a minority
of patients.
The incidence of PRES is unknown, but it has been
reported worldwide with a slight female predominance
[5,11,14]. PRES can affect both young and old, with the
mean age falling within the third or fourth decade. It is
traditionally thought as a monophasic illness, but recur-
rent cases have been reported [15]. Underlying comorbidi-
ties are usually present, contributing to acute hypertension
or endothelial dysfunction, or both. A recent retrospective
review of PRES cases in German hospitals found acute
renal failure, immunosuppression, organ transplant, infec-
tion, and autoimmune disorder, among others, to be com-
mon associated comorbidities in PRES [14].
The differential diagnosis of PRES is broad, given its
non-specific clinical manifestations, and it needs to be
distinguished from other causes of headache, confusion,
and seizure. Severe neurological conditions such as en-
cephalitis, posterior circulation stroke, cerebral venous
sinus thrombosis, reversible cerebral vasoconstriction syn-
drome, and ictal and post-ictal states can have similar clin-
ical presentations as PRES and need to be considered as
possible diagnoses. PRES should be considered in all pa-
tients presenting with an acute confusional state associ-
ated with elevated blood pressure and/or an underlying
cause of endothelial dysfunction [5,6,16].
The putative pathophysiology behind PRES is that of
failed cerebral autoregulation. Cerebral blood flow (CBF)is maintained at a constant level across a range of mean
arterial pressures (MAP) by way cerebral autoregulation
[17]. Cerebral autoregulation is achieved by vasoconstric-
tion or dilation of resistance arterioles, resulting in rela-
tively consistent blood flow to the brain. Vasoconstriction
and dilation are thought to be caused by a direct myogenic
response [18], and it is when the thresholds of adaptation
are surpassed that cerebral dysregulation occurs. When
resistance arterioles can no longer respond to increasing
MAPs, CBF can increase unchecked, leading to elevation
of filtration pressures in the capillary beds, and resulting
in extrasavation of plasma in the surrounding brain par-
enchyma leading to cerebral edema [17]. The posterior
circulation is more at risk of developing edema due to
decreased sympathetic innervation as compared to the
anterior circulation [19], and thus a decreased ability to
autoregulate.
Cerebral dysregulation can also result in the break-
down of the blood-brain barrier (BBB). The BBB con-
sists of vascular endothelium with tight intercellular
junctions, a basement membrane, and surrounding glial
cells. Animal studies have shown that the vascular endo-
thelium is the main barrier in keeping fluids and mole-
cules in their respective intra- and extravascular spaces
[20,21]. The extravasation of plasma occurs through
the tight junctions as well as through pinocytosis in
experimentally-induces hypertension [21]. From this, the
cerebral dysregulation seen in PRES can be a consequence
of increased filtration pressure at the level of the capillary
beds, which in turn overcomes the vascular endothe-
lium and tight intercellular junctions of the BBB. The
result is endothelial dysfunction and surrounding vaso-
genic edema.
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ent variable in the development of PRES. There are
reports of PRES with normal or minimally elevated blood
pressures [7-9], which do not fit within the paradigm of an
overwhelmed cerebral autoregulation. These cases, how-
ever, involved a systemic illness (e.g. sepsis or eclampsia)
or introduction of a medication (e.g. cyclosporine A) that
is thought to disrupt the BBB. The disruption of the BBB
allows seepage of fluid into the surrounding brain tissues,
resulting in cerebral edema that is clinically and radio-
graphically indistinct from PRES. It has also been pos-
tulated that damaged endothelium can impair cerebral
autoregulation and thus lower the threshold for dysregula-
tion [6]. It seems as if PRES can result from increases in
blood pressure that overcomes cerebral autoregulation
and the BBB, or it can occur independently in conditions
that damage or impair the BBB.
Patients with ESRD likely have baseline endothelial dys-
function secondary to ongoing uremia [22]. Endothelial
dysfunction may impede cerebral autoregulation, allowing
for extravasation of fluid at much lower MAPs, resulting
in vasogenic edema, and subsequently PRES. Indeed, PRES
has been reported in cases of uremic encephalopathy with
near normal blood pressures [23,24], again suggesting that
endothelial dysfunction is an independent variable for de-
veloping PRES.
A number of medications have been implicated in indu-
cing PRES, including erythropoietin [25], which is com-
monly prescribed to ESRD patients to treat the associated
normocytic anemia. Erythropoietin works by stimulating
the bone marrow to release more reticulocytes [26], and is
known to induce or exacerbate hypertension in ESRD pa-
tients [27]. This worsening of blood pressure may play a
role cerebral dysregulation, and ultimately PRES.
Medication withdrawal has also been implicated in the
development of PRES. Nakabou and colleagues report a
case of PRES following the discontinuation of antihyper-
tensive medication in a man with ESRD [28], and reso-
lution of symptoms when antihypertensives were restarted.
Clonidine, which can cause a rebound hypertension if dis-
continued quickly [29], has also been implicated in PRES
[6]. It is possible that our patient was not taking hisTable 1 Clinical summary of PRES in PD patients
Case study Age and sex Presentation Blood pressure
Kitamura et al, [30] 24 yo male Decreased LOC, seizure 170/80 mmHg
Ogawa et al, [31] 24 yo female HA, generalized seizure,
decreased LOC
190/117 mmHg
Girisgen et al, [15] 11 yo male HA, agitation, seizure 135/95 mmHg
160/100 mmHg
Delanty et al, [25] 12 yo male HA, lethargy, visual
disturbances, seizure
220/120 mmHgmedication in the hours leading up him presentation,
resulting in a rebound hypertension, and thus exacerbating
a process already underway.
There is a myriad of literature of PRES occurring in
conditions that cause acute renal failure, but only four
cases of PRES occurring in patients with ESRD receiving
PD. Kitamura and colleagues [30] reported the first case
of PRES in an adult patient receiving PD. The case in-
volved a 24-year-old male who presented with decreased
level of consciousness and generalized tonic-clonic seizure.
Blood pressure was measured at 170/80 mmHg, and medi-
cations included erythropoietin. The authors surmised that
the root cause of PRES in his case was poor compliance
with his PD and blood pressure medications. Symptoms re-
solved with aggressive blood pressure and volume control.
Abnormalities initially found on MRI brain had resolved
when follow-up imaging was undertaken one-month later.
Ogawa and colleagues [31] describe a case of PRES in
a 24-year-old Japanese woman receiving PD. She pre-
sented with severe headache, generalized seizures, and
decreased level of consciousness. Systolic blood pressure
was reported at being around 200 mmHg the morning
of the incident. The patient’s clinical picture improved
with aggressive antihypertensive therapy and increased
PD dose. Initial MRI abnormalities normalized 8 days after
admission.
Girisgen and colleagues [15] describe recurrent PRES
in a young boy receiving PD. He presented with headache
and seizure, and the authors were concerned about an
underlying infection. Blood pressure was initially mea-
sured at 135/95 mmHg. The second instance of PRES was
associated with a presenting blood pressure of 160/100
mmHg, but no sign of underlying infection. With blood
pressure and volume control, discontinuation of erythro-
poietin, and treatment of a presumed underlying infection
in the first presentation, the patient’s seizures and visual
symptoms abated and follow-up imaging normalized one
month after each instance of PRES. As the boy was on PD
for over a decade, the occurrence of PRES could not be
linked to the initiation of dialysis.
Delanty and colleagues [25] provide a case of PRES





Erythropoietin Poor compliance with
PD and medication
BP management and volume
control (PD and HD)
None listed Poor compliance with
PD and medication
AED, intubation, BP control,
and increased PD dose
Erythropoietin Underlying infection BP control, volume control,
and treatment of infection
Erythropoietin None given AED and discontinuation
of Erythropoietin
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ache, lethargy, visual disturbances, and generalized tonic-
clonic seizure. Blood pressure on presentation was 220/120
mmHg and medications included erythropoietin. Blood
pressure normalized and clinical symptoms abated when
erythropoietin was withdrawn.
All four of these cases share disturbed level of con-
sciousness and seizure as part of their presentation, which
is consistent with the PRES literature [3,4]. All patients
were hypertensive on presentation as well, save for the ini-
tial presentation of the young boy as described by Girisgen
and colleagues [15], who had a blood pressure of 135/95
mmHg. The development of PRES in this case could have
been due to underlying endothelial dysfunction at the
time, since it was thought that the boy had an underlying
infection. Not surprisingly, three of the four patients were
taking erythropoietin, which may have contributed to their
development of PRES. Interestingly, one of the cases de-
scribed an improvement in blood pressure and resolution
of symptoms simply by discontinuing erythropoietin [25].
Blood pressure control was paramount in all cases for
the resolution of symptoms and the reversal of imaging
abnormalities. Volume control was a significant factor
in managing blood pressure in two of the cases [15,30]
(Table 1).
Conclusion
This is to the best of our knowledge the third report of
PRES in an adult patient receiving PD. The cause of this
patient’s episode of PRES was likely multifactorial, stem-
ming from the complications of ESRD, poor compliance
with PD, medication side effects and possibly withdrawal.
We reviewed the literature surrounding PRES and PD and
found that the presentation, treatment, and final resolution
of this case is consistent with the PRES literature. We feel
that it is highly likely that all ESRD patients, including
those receiving PD, are at an increased risk of developing
PRES due to ongoing hypertension, endothelial dysfunc-
tion, and medication complications. It is also plausible that
PRES is under recognized in ESRD patients, and only the
extreme cases are brought to medical attention, or alterna-
tively, are recognized by healthcare providers. It is there-
fore important for physicians caring for ESRD patients
to consider PRES in all patients presenting with neuro-
logic complaints. PRES is highly treatable when recognized
early, and as the name suggests, is reversible; however,
longstanding neurologic sequelae can be had if it is not
recognized and addressed early on.
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